Theolytics, a clinical-stage biotechnology company, has appointed David Apelian as chief executive as the company advances its first clinical trial with lead candidate THEO-260 in ovarian cancer. Dr Apelian brings 25 years of experience in drug development and in multiple therapeutic areas, including immuno-oncology and cancer vaccines. He was the founding CEO of BlueSphere Bio Inc, where he was instrumental in developing a personalised cancer cell therapy programme and securing $105 million Series B funding.
He also was chief medical officer at Achillion Pharmaceuticals Inc. Dr Apelian has a PhD in biochemistry from Rutgers University and an MD from the University of Medicine and Dentistry of New Jersey, both US.
Theolytics announced the appointment on 17 December 2024.
Copyright 2025 Evernow Publishing Ltd.